Background and objectives The International Society of Blood Transfusion (ISBT) Working Party for Red Cell Immunogenetics and Blood Group Terminology meets in association with the ISBT congress and has met three times since the last report: at the international meetings held in Dubai, United Arab Emirates, September 2016 and Toronto, Canada, June 2018; and at a regional congress in Copenhagen, Denmark, June 2017 for an interim session.
Methods As in previous meetings, matters pertaining to blood group antigen nomenclature and classification were discussed. New blood group antigens were approved and named according to the serologic and molecular evidence presented.
Results and conclusions
Fifteen new blood group antigens were added to eight blood group systems. One antigen was made obsolete based on additional data. Consequently, the current total of blood group antigens recognized by the ISBT is 360, of which 322 are clustered within 36 blood groups systems. The remaining 38 antigens are currently unassigned to a known system. Clinically significant blood group antigens continue to be discovered, through serology/sequencing and/or recombinant or genomic technologies.
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A key role for the Working Party on Red Cell Immunogenetics and Blood Group Terminology is to review reports for blood group systems, antigens and associated blood group alleles. Historically, endorsement has occurred at the biennial ISBT International Congress. Curated blood group antigens and allelic tables are also reviewed by members in the interim who may also meet in the alternate years at regional congress meetings when there is a sufficient member quorum present (Appendix 1).
A total of 15 blood group antigens were added to eight of the current blood group systems (Table 1) . One antigen was made obsolete following additional investigation of the original antibody. This brings the current total of recognized blood group antigens to 360, of which 322 are clustered within 36 blood groups systems.
Thus, there remain 38 serologically defined antigens that have not been assigned to a blood group system. Fourteen of those reside in one of five collections (the 200 series), 17 in the low-prevalence series (700) and a further seven are in the 901 series (prevalence >90%).
New blood group antigens
System 2: MNS One antigen has been added to the MNS system, JENU (MNS49). An alloantibody to a high-prevalence antigen was shown by epitope mapping to be directed at the amino acids 38-SYISSQTNGETG-49 of glycophorin B (GPB). The antibody maker was a thalassemia patient of Thai origin who was shown to lack normal GPB, but who was homozygous for the GYP.Mur hybrid (GYP*501). Thus, JENU is a high-prevalence antigen on GPB that is absent from the GP.Mur hybrid [1] . The epitope defined above is interrupted in the hybrid protein. The name JENU combines JE, from the first two letters of the surname of the patient who made the JENU antibody, and NU, from the high frequency 'N' and U antigens present on GPB. Antibodies to an apparent high-prevalence Lutheran system antigen were identified in the plasma of two Turkish sisters during their respective pregnancies. Their RBCs were mutually compatible, and subsequent molecular analysis of BCAM identified homozygosity for two nucleotide changes. The first is a synonymous change in exon 3, c.324G>A (p.Gly108Gly) known to be present in approximately 3-4% of the general population. The second one was found in exon 9, c.1184G>A, and predicts the amino acid change p.Arg395His on the fourth Ig superfamily domain of the Lutheran glycoprotein. The antigen was named LUYA (LU27) after the proposita [4] .
System 6: Kell
A tragic neonatal death due to haemolytic disease led to the identification of an antibody to a novel low-prevalence antigen in the Kell blood group system [5] . The antigen, KEAL (KEL39; named after the proposita), was shown to be encoded by the substitution c.877C>T (p.Arg293Trp) in exon 8 of KEL, and inheritance could be demonstrated in three generations. KEAL is antithetical to the high-prevalence antigen, KHUL (KEL37) [6] .
System 11: Yt
The Yt blood group system has more than doubled in size in the past 3 years. Use of recombinant protein reagents has been very helpful in teasing apart complex mixtures of antibodies, and three new high-prevalence antigens have been added to this system by Thornton and colleagues at the International Blood Group Reference Laboratory. In the first case, soluble recombinant Yt protein (srYt) successfully inhibited an additional unknown antibody to a high-prevalence antigen in plasma from an acute myeloid leukaemia patient that contained anti-c, . Subsequent sequence analysis of ACHE demonstrated homozygosity for the mutation c.266G>A in exon 2, encoding an amino acid change p.Gly89Glu in acetylcholine-esterase AChE) [7] . The new antigen is named YTEG (YT3) after the proband's name.
An additional antibody to a high-prevalence antigen was found in the plasma of a pregnant woman with antiJk a . Use of a recombinant soluble antigen panel demonstrated Yt specificity although the patient's RBCs typed Yt(a+b-), YTEG+. ACHE sequencing confirmed the proband and her serologically compatible brother to be YT*A/A and revealed a novel homozygous mutation c.169G>A in exon 2, encoding p.Gly57Arg change in AChE. The antigen (YT4) has been named YTLI (after the referring centre in Liverpool) [8] .
The third addition to the Yt blood group system followed the serological investigation of plasma from a young pregnant woman with sickle cell disease. Her plasma contained multiple antibodies, including anti-Fy a ,
-Js a and an antibody that reacted with all phenotypically similar RBCs. Again, reactivity with the latter was inhibited by srYt although antibodies to Yt a , YTEG and YTLI were excluded. Sequencing of ACHE identified a novel homozygous mutation c.101G>A in exon 2, encoding p.Arg34Gln change in AChE. The antigen (YT5) has been named YTOT, also after the referring laboratory [8] .
System 21: Cromer A novel Inab-like phenotype has been molecularly characterized after an antibody that was compatible only with high-prevalence antigen. The antigen (CROM19) has been named CROK after the patient [9] . Exome sequencing was used to resolve an unidentified antibody to a high-prevalence antigen in the plasma of a 103-year-old woman of French Corsican descent. Her history showed a single pregnancy in 1949, and the antibody was first detected in 2002. When new samples were received for investigation in 2016, DNA was isolated and exome sequenced, which revealed homozygosity for c.713G>A in exon 6 of the CD55 gene, predicted to cause a p.Gly238Glu amino acid change. Her son was found to be heterozygous for the same mutation. Cromer specificity of the antibody was subsequently confirmed when RBCs of the Inab phenotype became available. The antigen (CROM20) was named CORS to reflect the patient's origin [10] .
System 23: Indian
INRA (IN5) is a new high-prevalence antigen in the Indian blood group system and was named after the patient. The defining antibody was present in the plasma of a female patient from Surat in the Indian state of Gujarat and demonstrated the classic absence of reactivity with papain-treated RBCs characteristic of Indian blood group system antibodies. The antibody was compatible only with the RBCs of the patient's brother. Sequence analysis of CD44 demonstrated homozygosity for a novel homozygous synonymous mutation c.255C>T in exon 3 (p.His85His), and for a novel homozygous missense mutation c.449G>A in exon 5, encoding p.Arg150His [11] .
Soluble recombinant CD44 helped to resolve the identity of an antibody to a high-prevalence antigen in the plasma of a Sri Lankan patient with suspected In specificity. Both the patient and his serologically compatible brother typed In(a-b+), INFI+, INRA+. Sequencing of CD44 revealed homozygosity in both siblings for a mutation c.276C>A, which predicts an amino acid change p.His92Gln. The antigen (IN6) has been named INSL to reflect the origin of the patient [12] .
System 36: Augustine
The Augustine system continues to expand since its discovery in 2015 [13] . A case of severe HDFN led to the discovery of a low-prevalence antigen that was shown by targeted exome sequencing to be encoded by SLC29A1. DNA from both the infant and father revealed a mutation c.1159A>C, in exon 12 predicting an amino acid change of p.Thr387Pro. In an extended family study, six paternal family members carried the nucleotide substitution; RBCs from these six members showed incompatibility with the mother's plasma, demonstrating that serological reactivity segregated with the mutation. The predicted amino acid change is four residues from the amino acid that defines the At a antigen in the fifth extracellular loop. The antigen (AUG3) was named ATML after the initials of the patient [14] . A novel high-prevalence antigen in this system was defined in a follow-up investigation of a long-time unresolved antibody in a female patient. Targeted exome sequencing in this case revealed homozygosity for c.242A>G in the SLC29A1 gene that changes p.Asn81Ser. Confirmatory serology showed that the plasma was compatible with AUG:-1 RBCs, which are the null phenotype in this blood group system. The antigen (AUG4) was named ATAM after the proband's name [15] .
Other changes to blood group systems
System 28: GLOB When PX2 was assigned to this blood group system, it was moved from the GLOB collection (see below) into the GLOB blood group system and assigned the number GLOB2 (028002) [16] . This has caused confusion with old records of rare RBCs in some laboratories; thus, the decision was taken to reassign PX2 as GLOB4, and the numbers GLOB2 and GLOB3 have been made obsolete. A current list of obsolete numbers is shown in Table 2 .
System 30: RHAG Two independent investigations have shown that the polymorphism RHAG c.808G>A (p.Val270Ile) does not encode a low-prevalence antigen as first described. In a study of RHD, RHCE and RHAG variation examined by wholeexome sequencing of samples from children with sickle cell disease, Chou et al. have shown this polymorphism to be common, with 14Á6% of samples demonstrating heterozygosity [17] . Supplementary serological investigation of the original sample, reported following a case of severe haemolytic disease of the foetus and newborn [18] , revealed the antibody to be anti-s D (MNS23). Consequently, RHAG4 has been made obsolete. 
